About This Fund
ARCH Venture Fund XIII is ARCH Venture Partners' largest fund to date, closing at over $3 billion in September 2024. The fund focuses on founding and growing early-stage biotechnology companies that leverage AI-driven biological insights to prevent, detect, and cure disease. Early portfolio companies include ArsenalBio, Metsera, Mirador Therapeutics, and Xaira Therapeutics. Limited partners include Alaska Permanent Fund Corporation and Rockefeller Brothers Fund.